Evoke Pharma Highlights GIMOTI as a Leading Solution for Gastroparesis Treatment as Domperidone Supply Ends FDA posts update as mechanism to obtain unapproved Domperidone expected to lose supply in early 2025 Gimoti remains only approved drug shown to reduce hospitalizations, emergency room and medical...

Global Gastroparesis Treatment Market to Surpass US$ 10,726.0 Million by 2030, Says Coherent Market Insights (CMI) Seattle, Aug. 18, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global gastroparesis treatment market is estimated to be valued at US$ 8,061.9 million in 2022 and expected to...

CinDome Pharma Announces Start of Phase 2 Trial of Deuterated Domperidone (CIN-102) CINCINNATI, Sept. 19, 2019 (GLOBE NEWSWIRE) -- CinDome Pharma, Inc. (“CinDome”), a company whose lead product is deuterated domperidone (CIN-102), today announced that is has enrolled the first...

Neurogastrx Appoints Baxter Phillips III as President and Chief Executive Officer CAMPBELL, Calif., Nov. 03, 2015 (GLOBE NEWSWIRE) -- Neurogastrx, a biopharmaceutical company engaged in developing novel drugs for gastrointestinal disorders, today announced the appointment of...